Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Key facts

Sponsor

Vanderbilt-Ingram Cancer Center

Principal Investigator

Sanjay Mohan, MD

Vanderbilt-Ingram Cancer Center

Intervention

Azacitidine Subcutaneous Injection or Intravenous Infusion(drug)

Enrollment

71 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2023

Study locations (5)

• University of Miami Miller School of Medicine, Miami, Florida, United States
• University of Kansas Cancer Center, Westwood, Kansas, United States
• Memorial Sloan-Kettering, New York, New York, United States
• University of Rochester Medical Center, Rochester, New York, United States
• Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic/myeloproliferative disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05564390
  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06532084
  Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE2NCT05788679
  A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
  Karolinska University Hospital
• RECRUITINGPHASE2NCT04493164
  CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
  M.D. Anderson Cancer Center

See all trials for Myelodysplastic/myeloproliferative disease →